Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. PTC Therapeutics Inc shares valued at $89,081 were sold by Boulding Mark Elliott on May 15 ’25. At $46.18 per share, Boulding Mark Elliott sold 1,929 shares. The insider’s holdings dropped to 103,901 shares worth approximately $5.08 million following the completion of this transaction.
Also, Boulding Mark Elliott sold 883 shares, netting a total of over 40,636 in proceeds. Following the sale of shares at $46.02 each, the insider now holds 103,901 shares.
Before that, Boulding Mark Elliott had added 883 shares to its account. In a trade valued at $40,640, the Officer bought PTC Therapeutics Inc shares for $46.02 each.
As published in their initiating research note from Truist on June 17, 2025, PTC Therapeutics Inc [PTCT] has been a Buy and the price target has been revised to $80. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early May. As of May 07, 2025, Citigroup has increased its “Sell” rating to a “Neutral” for PTCT. Earlier on March 11, 2025, BofA Securities upgraded its rating. Their new recommendation was “a Neutral” for PTCT stock which previously was a “an Underperform”.
Analyzing PTCT Stock Performance
On last trading session,, PTC Therapeutics Inc [NASDAQ: PTCT] plunged -1.47% to $48.89. The stock’s lowest price that day was $48.18, but it reached a high of $49.435 in the same session. During the last five days, there has been a drop of approximately -3.85%. Over the course of the year, PTC Therapeutics Inc shares have jumped approximately 33.87%. Shares of the company reached a 52-week high of $58.38 on 03/17/25 and a 52-week low of $35.95 on 05/06/25.
Support And Resistance Levels for PTC Therapeutics Inc (PTCT)
According to the 24-hour chart, there is a support level at 48.24, which, if violated, would cause prices to drop to 47.58. In the upper region, resistance lies at 49.49. The next price resistance is at 50.09. RSI (Relative Strength Index) is 46.84 on the 14-day chart, showing neutral technical sentiment.
Is PTC Therapeutics Inc subject to short interest?
Stocks of PTC Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.26 million shares to 4.75 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 5.01 million shares. A decline of -5.37% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.06 of the overall float, the days-to-cover ratio (short ratio) decline to 3.06.
Which companies own the most shares of PTC Therapeutics Inc (PTCT)?
In terms of PTC Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 62 in the next 12 months, up nearly 24.95% from the previous closing price of $49.62. Analysts anticipate PTC Therapeutics Inc stock to reach 66 by 2025, with the lowest price target being 58. In spite of this, 7 analysts ranked PTC Therapeutics Inc stock as Hold at the end of 2025. On March 07, 2025, Scotiabank assigned a price target of “a Sector perform” to the stock and initiated coverage with a $55.
